SCHEMBL16645200

SCHEMBL16645200

CC(C)(C)OC(=O)N1CCc2cc(NC(=O)CC(C)(O)C(F)(F)F)ccc2C1

nearest known ligand 0.56

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.56
NR1H2 P55055 1/20 0.50
NPC1 O15118 1/20 0.49
RAB9A P51151 1/20 0.49
KDM4E B2RXH2 1/20 0.45
PIK3CA P42336 1/20 0.45
MTOR P42345 1/20 0.45
NAMPT P43490 3/20 0.44
JAK2 O60674 1/20 0.44
JAK3 P52333 1/20 0.44
PTK2 Q05397 1/20 0.44
TMPRSS2 O15393 3/20 0.44
GPR119 Q8TDV5 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
IGF1R P08069 1/20 0.42
ABHD6 Q9BV23 2/20 0.41
HDAC1 Q13547 1/20 0.41
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16645220 0.90 ESR2 (0.61) ESR2NR1H2NPC1RAB9AKDM4E
SCHEMBL16645222 0.89 ESR2 (0.62) ESR2NR1H2NPC1RAB9AKDM4E
SCHEMBL17969236 0.88 TMPRSS2 (0.49) ESR2NPC1RAB9AKDM4ETMPRSS2
SCHEMBL16645223 0.87 ESR2 (0.57) ESR2NR1H2NPC1RAB9AKDM4E
SCHEMBL29728578 0.87 ESR2 (0.57) ESR2NR1H2NPC1RAB9AKDM4E
SCHEMBL3729030 0.84 ESR2 (0.62) ESR2NR1H2NPC1RAB9AKDM4E
SCHEMBL20704305 0.83 ESR2 (0.63) ESR2NR1H2NPC1RAB9APIK3CA
SCHEMBL31174284 0.82 ESR2 (0.67) ESR2NR1H2NPC1RAB9AKDM4E
SCHEMBL31174286 0.82 ESR2 (0.67) ESR2NR1H2NPC1RAB9AKDM4E
SCHEMBL1187860 0.80 ESR2 (0.62) ESR2NR1H2NPC1RAB9APIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2020191359-A1 CANCER COMBINATION THERAPIES UTILIZING A NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITOR IN COMBINATION WITH A NICOTINAMIDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY PRECURSOR FRED HUTCHINSON CANCER RESEARCH CENTER (US) 2020-09-24 WO disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY 2016-08-11 US disclosed
WO-2015054060-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS ELI LILLY AND COMPANY (US) 2015-04-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160229835-A1 NOVEL PYRIDYLOXYACETYL TETRAHYDROISOQUINOLINE COMPOUNDS USEFUL AS NAMPT INHIBITORS NAMPT, NAPRT, NNMT ESR2 4495/4885NR1H2 2307/4885NPC1 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.